MENLO PARK, Calif., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that data from its DRM04 and olumacostat glasaretil (formerly DRM01) clinical programs will be presented during poster sessions at the 75th Annual Meeting of the American Academy of Dermatology (AAD) being held in Orlando, March 3-7, 2017. Primary efficacy and safety data from both the DRM04 Phase 3 clinical program in primary axillary hyperhidrosis and the olumacostat glasaretil Phase 2b clinical trial in acne vulgaris were previously reported.
New data highlighting the time to efficacy response observed during the 4-week treatment period from the DRM04 Phase 3 clinical program and the 12-week treatment period from the olumacostat glasaretil Phase 2b clinical trial will be presented. The data from both clinical programs will be highlighted in separate poster sessions during AAD.
“Dermira is advancing clinical programs in primary axillary hyperhidrosis and acne vulgaris, both areas of great unmet need where the standard of care hasn’t meaningfully advanced in several decades,” said Eugene A. Bauer, M.D., chief medical officer of Dermira and a dermatologist. “We are pleased to present new efficacy and safety data from both clinical programs, which demonstrate that patients who received both investigational therapies began to experience clinical benefit quickly following initial topical administration when compared to vehicle. Ultimately, our goal is to build on the significant scientific advances being made in understanding skin biology to address the needs of the millions of people living with these conditions.”
Posters of Interest:
Title: Olumacostat Glasaretil (formerly DRM01) for the Treatment of Acne Vulgaris: Primary Results from the DRM01-ACN02 Phase 2b Randomized Controlled Trial
Date and Time: March 3, 2017; 10:35 a.m. – 10:40 a.m. ET
Location: Available as an ePoster in Centre 1
Abstract Number: 4835
Title: DRM04 for the Treatment of Primary Axillary Hyperhidrosis: Primary Results from the ATMOS-1 and ATMOS-2 Phase 3 Randomized Controlled Trials
Date and Time: March 3, 2017; 1:45 p.m. – 1:50 p.m. ET
Location: Available as an ePoster in Centre 2
Abstract Number: 4834
Dermira is a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases. Dermira’s product pipeline includes three Phase 3 product candidates that target significant unmet needs and market opportunities: DRM04, in development for the treatment of primary axillary hyperhidrosis (excessive underarm sweating); CIMZIA® (certolizumab pegol), in development in collaboration with UCB Pharma S.A. for the treatment of moderate-to-severe chronic plaque psoriasis; and olumacostat glasaretil, in development for the treatment of acne vulgaris. Dermira is headquartered in Menlo Park, Calif. For more information, please visit www.dermira.com.
In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Dermira uses its website (www.dermira.com) and LinkedIn page (https://www.linkedin.com/company/dermira-inc-) as channels of distribution of information about its company, product candidates, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Dermira may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Dermira’s website and LinkedIn page in addition to following its SEC filings, press releases, public conference calls and webcasts.
DRM04 is formulated as a topical, once-daily anticholinergic agent that is currently in clinical development for the treatment of primary axillary hyperhidrosis. DRM04 is designed to block sweat production by inhibiting the interaction between acetylcholine and the cholinergic receptors responsible for sweat gland activation.
About Olumacostat Glasaretil
Olumacostat glasaretil is a novel, small molecule designed to target sebum production following topical application. Sebum is an oily substance made up of lipids produced by glands in the skin called sebaceous glands, and excessive sebum production is an important aspect of acne that is not addressed by available topical therapies. Olumacostat glasaretil is designed to exert its effect by inhibiting acetyl coenzyme-A carboxylase, an enzyme that plays an important role in the synthesis of fatty acids, a type of lipid that represents an essential component of the majority of sebum lipids.
The information in this press release contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. This press release contains forward-looking statements that involve substantial risks and uncertainties, including statements with respect to Dermira’s goal to build on the significant scientific advances being made in understanding skin biology to address the needs of the millions of patients living with primary axillary hyperhidrosis and acne vulgaris. These statements deal with future events and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to the design, implementation and outcomes of Dermira’s clinical trials, including related to further analysis of the results of our studies; the outcome of future discussions with regulatory authorities relating to Dermira’s clinical programs; Dermira’s dependence on third-party clinical research organizations, manufacturers and suppliers; Dermira’s ability to obtain necessary additional capital; and Dermira’s ability to continue to stay in compliance with applicable laws and regulations. You should refer to the section entitled “Risk Factors” set forth in Dermira’s Annual Report on Form 10-K, Dermira’s Quarterly Reports on Form 10-Q and other filings Dermira makes with the SEC from time to time for a discussion of important factors that may cause actual results to differ materially from those expressed or implied by Dermira’s forward-looking statements. Furthermore, such forward-looking statements speak only as of the date of this press release. Dermira undertakes no obligation to publicly update any forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise, except as required by law.
CONTACT: Contacts: Media: Erica Jefferson Senior Director, Head of Corporate Communications 650-421-7216 firstname.lastname@example.org Investors: Andrew Guggenhime Chief Operating Officer and Chief Financial Officer 650-421-7200 email@example.com Robert H. Uhl Westwicke Partners Managing Director 858-356-5932 firstname.lastname@example.org